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Background
The literature of the past four decades contains several
scattered reports that demonstrate the existence of two
different 3’,5’-cCMP degrading enzymes with distinct
substrate affinity and specificity. The so-called “cCMP-
specific” PDE was isolated from disrupted L-1210 leuke-
mia cells [1] and from rat liver [2,3], shows an extremely
high 3’,5’-cCMP KM value of up to 9 mM and seems to
be activated by iron [1]. This enzyme prefers 3’,5’-cCMP
over other cyclic nucleotides. The other enzyme is called
“multifunctional cCMP PDE” and was isolated from pig
liver [3-5], rat liver [6,7] and human liver [8]. This
enzyme shows a 3’,5’-cCMP KM value in the range of
100-300 µM and is additionally degrading 2’,3’-cCMP as
well as the 2’,3’- and 3’,5’-isomers of cUMP, cAMP,
cGMP and cIMP. The multifunctional cCMP PDE is
inhibited by inorganic phosphate and AMP. Both
enzymes are calmodulin-insensitive, IBMX-resistant and
show a low molecular weight of <35 kDa, which is
uncommon for the “classic” phosphodiesterases. How-
ever, the exact amino acid sequence and identity of
these proteins remain elusive.
Our project aims at a clear and unequivocal determina-
tion of amino acid sequence and identity of these elusive
cCMP-degrading enzymes by analyzing and purifying the
cCMP degrading activity of organ extracts and biological
fluids (e.g. serum). Moreover, we re-investigate well-
known “classic” PDEs in enzymatic assays to identify a
potential 3’,5’-cCMP degrading activity.
Materials and methods
The substrates and products of PDE reactions are
detected and quantified with high accuracy by a highly
sensitive HPLC-MS/MS method (triple quadrupol mass
spectrometer) which is established in our institute. This
method enables us for the first time to unequivocally
identify cyclic nucleotides and their degradation pro-
ducts in biological samples.
We assay organ extracts and biological fluids for
cCMP PDE activity and use the standard methods of
protein biochemistry to identify, concentrate and purify
these enzymes (Western blot, SDS PAGE, fractionated
precipitation of proteins by addition of ammonium sul-
fate or lowering pH value). A very important part of our
methodology is the use of an FPLC system for protein
separation. The identity of purified proteins will be
determined by analyzing a fingerprint of the fragments
in mass spectrometry and comparing the results with
the content of biological databases. In addition, we char-
acterize the enzymatic activity of commercially available
recombinant PDEs.
Results
A screen of 13 commercially available recombinant
PDEs revealed that these enzymes show unexpectedly
broad substrate specificity and also degrade “exotic” cyc-
lic nucleotides like cUMP, cIMP, cXMP and cTMP [9].
Most interestingly, however, only one of the tested
enzymes, PDE 7A1, degraded cCMP.
In addition, we have identified a heat-sensitive cCMP-
degrading activity in certain commercially available
batches of fetal bovine serum. This enzymatic activity
can be considerably enhanced by filtration of the serum
through centrifugation filtration devices (30 kDa cutoff).
Results from FPLC chromatography suggest that this
enzyme may be associated with larger protein com-
plexes, one of the components probably being serum
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Conclusion
Our PDE 7A1 data and the heat-sensitive cCMP-degrading
activity detected in bovine serum samples demonstrate that
cCMP PDEs really exist. We plan to characterize PDE 7A
in more detail in enzyme kinetics experiments using fluor-
escent cNMP analogues. Moreover, we plan to purify and
concentrate the cCMP-degrading activity in bovine serum
in order to further characterize it with various substrates
and inhibitors. In addition, we will also test organ extracts,
specifically from liver (mouse and pig) in order to confirm
the results previously reported in the literature and to
finally reveal the identity of the “cCMP-specific” and “mul-
tifunctional” cCMP-PDE.
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